These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31971288)

  • 21. Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Ther Drug Monit; 2019 Aug; 41(4):528-532. PubMed ID: 31259882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
    Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.
    Kim JM; Lee KW; Song GW; Jung BH; Lee HW; Yi NJ; Kwon CD; Hwang S; Suh KS; Joh JW; Lee SK; Lee SG
    Clin Mol Hepatol; 2016 Sep; 22(3):366-371. PubMed ID: 27729628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis.
    Azarfar A; Ravanshad Y; Mehrad-Majd H; Esmaeeli M; Aval SB; Emadzadeh M; Salehi M; Moradi A; Golsorkhi M; Khazaei MR
    Saudi J Kidney Dis Transpl; 2018; 29(6):1376-1385. PubMed ID: 30588970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies.
    Yin S; Song T; Li X; Xu H; Zhang X; Jiang Y; Lin T
    Curr Pharm Des; 2019; 25(21):2394-2403. PubMed ID: 31333109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
    Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
    Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrolimus and Single Intraoperative High-dose of Anti-T-lymphocyte Globulins Versus Tacrolimus Monotherapy in Adult Liver Transplantation: One-year Results of an Investigator-driven Randomized Controlled Trial.
    Iesari S; Ackenine K; Foguenne M; De Reyck C; Komuta M; Bonaccorsi Riani E; Ciccarelli O; Coubeau L; Lai Q; Gianello P; Lerut J
    Ann Surg; 2018 Nov; 268(5):776-783. PubMed ID: 30307410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring.
    Melilli E; Crespo E; Sandoval D; Manonelles A; Sala N; Mast R; Padulles A; Grinyo JM; Bestard O; Cruzado JM
    Transpl Int; 2015 Nov; 28(11):1283-90. PubMed ID: 26088437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
    Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
    Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
    Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
    Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction.
    Han JW; Joo DJ; Kim JH; Rha MS; Koh JY; Park HJ; Lee JG; Kim MS; Kim SI; Shin EC; Park JY; Park SH
    Am J Transplant; 2020 Aug; 20(8):2058-2069. PubMed ID: 31965710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
    Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic immunosuppressants.
    Medeiros M; Lumini J; Stern N; Castañeda-Hernández G; Filler G
    Pediatr Nephrol; 2018 Jul; 33(7):1123-1131. PubMed ID: 28733752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab: a single center experience.
    Masutani K; Kitada H; Tsuchimoto A; Yamada S; Noguchi H; Tsuruya K; Tanaka M; Iida M
    Clin Exp Nephrol; 2011 Apr; 15(2):264-8. PubMed ID: 21170758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
    Transpl Int; 2016 Feb; 29(2):216-26. PubMed ID: 26442829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
    Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
    Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.